Expanded Access Policy

Expanded access, also known as “compassionate use,” refers to the use of an investigational new drug outside of a clinical trial for patients with serious or life-threatening conditions who have exhausted their treatment options and are not eligible for, or able to participate in, a clinical trial.

KSQ Therapeutics, Inc. (“KSQ”) is committed to studying and developing our investigational therapies as part of clinical trials designed to generate adequate safety and efficacy data to evaluate the potential benefit of the therapy versus the risk, which can then be used to support regulatory approval of the investigational therapies.

Clinical trials and the subsequent regulatory approval of a new therapeutic option provides the path to long-term access to treatment. We believe that focusing on current and future clinical trial programs provides the best path to meet our goal of providing therapies to patients. As such, at this time, KSQ does not have an expanded access program (EAP) that allows patients to have access to our investigational therapies outside of enrollment in our clinical trials.

Information regarding our development programs and clinical trials can be found on our website or by visiting www.clinicaltrials.gov and searching for KSQ Therapeutics.

If applicable, this website will be updated with hyperlinks to the relevant expanded access information on www.clinicaltrials.gov upon activation. As authorized by the 21st Century Cures Act, KSQ reserves the right to revise this expanded access policy at any time.

If you have any questions regarding this policy or our clinical trials, please contact KSQ Therapeutics, Inc. at clinicalinfo@ksqtx.com. KSQ plans to respond to expanded access inquiries within seven (7) business days of receipt.